Format

Send to

Choose Destination
Schizophr Res. 2012 Dec;142(1-3):206-8. doi: 10.1016/j.schres.2012.08.003. Epub 2012 Oct 1.

DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs.

Author information

1
Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de Sao Paulo (UNIFESP), São Paulo, Brazil. vanessakaota@gmail.com

Abstract

We investigated the association of dopamine receptor D1 gene (DRD1) rs4532 polymorphism with antipsychotic treatment response in schizophrenia. We have analyzed 124 patients with schizophrenia, consisting of 59 treatment resistant (TR) and 65 non-TR. We found an association between G-allele and TR schizophrenia (p=0.001; adjusted OR=2.71). Setting the common AA-genotype as reference, the GG-homozygous presented a five-fold risk compared to AA-homozygous (p=0.010; OR=5.56) with an intermediate result for AG-genotype (p=0.030; adjusted OR=2.64). The DRD1 rs4532 polymorphism showed a dose-response gradient with increased risk for treatment resistance and may be a potential pharmacogenetic marker for antipsychotic drug treatment response.

PMID:
23036699
DOI:
10.1016/j.schres.2012.08.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center